Search PubMed⌕ Search

Biomedical subjects

J Rubin

Publications and source records attributed to J Rubin.

At least 343 records · Page 19Linked to original sources
PubMed1978

Evaluation of a fixed alternating treatment in patients with advanced breast cancer.

A total of 128 patients were randomly assigned to two induction treatment programs: Adriamycin and L-PAM versus Cytoxan, 5-Fluorouracil, and Prednisone in an effort to assess their primary capacity for objective response. The two regimens appeared quite comparable in this respect. The 100 patients who had achieved clinical benefit following initial treatment were subsequently randomly allocated to reveive either a fixed alternate treatment program involving the two drug regimens or were continued on the treatment program responsible for their initial improvement. Although those patients who received the fixed alternate treatment shcedule had a somewhat longer progression-free interval compared to the two single-treatment programs (median duration of 16 months versus 12 months, respectively), the three treatment programs including the fixed alternate treatment schedules had comparable median survivals of 21-24 months with little difference noted in survival curves at any point thus far in the analysis. There were no differences noted in survival for the fixed alternating treatment group of patients, with respect to which induction regimen had been utilized to achieve initial response. The toxicity for these treatment programs was tolerable and compatible with outpatient administration. Myelosuppression occurred in the vast majority of patients on either regimen but in both regimens was relatively platelet sparing.

Antineoplastic Agents↗
PubMed1978

Effects of ultrafiltration on solute clearances in cuprophan and cellulose hollow fiber dialyzers: in vitro and clinical studies.

Hollow fiber dialyzers are currently available with either regenerated cellulose or thinner walled cuprophan fibers. In vitro and clinical studies were undertaken to compare a cellulose with a cuprophan dialyzer in regard to (1) UF's, (2) small and large solute clearances at high and low TMP's, (3) SC's, and (4) effects of ultrafiltration on diffusive and convective components of clearances. The results show that per square meter of surface area, the cuprophan dialyzer has higher rates of UF per TMP and greater clearances, particularly of larger solutes; also with cuprophan the SC for vitamin B12 is higher. Thus all findings suggest greater permeability of cuprophan fibers. In both dialyzers, total clearances increased with UF by amounts compatible with predicted increases in convective transport; diffusive transport remained stable as TMP was increased.

Cellulose↗
PubMed1978

Phase II study of triazinate and pyrazofurin in patients with advanced breast cancer previously exposed to cytotoxic chemotherapy.

The purpose of this phase II clinical trial was to evaluate the effectiveness of triazinate and pyrazofurin in the treatment of advanced breast cancer. Although an occasional patient experienced stability of disease, neither agent, as employed in this study, was able to produce an objective antitumor effect in this group of patients with previous chemotherapeutic exposure. At the dosages used in this study, neither agent can be recommended for further treatment of advanced breast cancer.

Adult↗
PubMed1978

cis-Dichlorodiammineplatinum(II) alone followed by adriamycin plus cyclophosphamide at progression versus cis-dichlorodiammineplatinum(II), adriamycin, and cyclophosphamide in combination for adenocarcinoma of the lung.

Forty-one patients with proven metastatic adenocarcinoma of the lung were randomized into two comparable groups after stratification for performance status and presence of measurable or evaluable disease. Treatment 1 consisted of cis-dichlorodiammineplatinum(II) (P) at a dose of 15 mg/m2/day by iv push on Days 1--5 every 4 weeks. Upon progression or the onset of renal toxic effects, patients were crossed over to cyclophosphamide (C) at a dose of 400 mg/m2, and adriamycin (A) at a dose of 40 mg/m2, both given by iv push on Day 1 every 4 weeks. Treatment 2 (CAP-I) consisted of C-A in the same doses as above plus concurrent P, 40 mg/m2 by IV push on Day 1 every 4 weeks. Eight patients receiving P developed serum creatinine values greater than or equal to 1.5 mg/100 ml versus one patient receiving CAP-I (P = 0.05). Objective regressions occurred in two of 22 patients with P, five of 17 with C-A, and eight of 19 with CAP-I (P = 0.025; CAP-I versus P). There was a significant increase in the median duration of regression in patients responding to C-A following P (267 days) versus patients responding to CAP-I (95 days). The improved rate of response with CAP-I and the prolonged duration of response with C-A following P suggest a potentiating effect between P and C-A whether given simultaneously or sequentially.

Adenocarcinoma↗
PubMed1977

The use of neurolept analgesia for gastro-intestinal endoscopy.

A prospective double-blind study of the effects of sedation in 142 patients undergoing gastro-intestinal endoscopy was performed. Four regimens were studied (neurolept analgesia with and without topical anaesthesia, and anticholinergic and topical anaesthesia, with and without diazepam). Droperidol and fentanyl without topical anaesthesia yielded the best results as far as tolerance and side-effects were concerned. It is suggested that this form of neurolept analgesia be used for gastro-intestinal endoscopy.

Adolescent↗
PubMed1977

Premedication with flunitrazepam in gastro-intestinal endoscopy.

Administration of 2 mg flunitrazepam (Rohypnol; Roche) to patients before gastro-intestinal endoscopy caused significantly less anxiety and achieved significantly greater sedation than diazepam (Vallium; Roche). No differences were found between any of the trial groups with respect to ease of intubation, tolerance of the procedure, gastric peristalsis, and the state of the pylorus. Memory of the procedure was significantly less vivid in the groups who received 2 mg flunitrazepam, than in the other groups. The patients who received 2 mg flunitrazepam showed a significantly greater willingness to undergo a repeat procedure, both when asked immediately after the procedure, and when asked on the next visit. Pulse rate increased in all groups during the procedure. No change in respiratory rate or in systolic and diastolic blood pressure occurred in any group.

Anti-Anxiety Agents↗
PubMed1977

A phase II study of triazinate (NSC 139105) in advanced colorectal carcinoma.

Triazinate (Baker's Antifol, NSC 139105) was given to 28 patients as a single agent in the chemotherapy of advanced colerectal carcinoma. The dosage utilized was 250 mg/m2 intravenously, administered daily in three consecutive days. Patients were evaluated at three weeks, six weeks, and then monthly until progression was evident. Various immunologic determinants (i.e., DNCB sensitization, immunoglobulins, recall skin tests, lymphocyte blastogenesis, and circulating lymphocytes, T-cells and B-cells) were obtained prior to treatment and at each re-evaluation. The principal side effects were dermatitis, stomatitis, diarrhea, nausea, somnolence, and leukopenia. There was no discernable effect of Triazinate on the immunologic determinants tested. There was one complete response, and four partial responses, for an objective regression rate of 18%. This study suggests that Triazinate has a definite, though limited, effect on advanced colorectal carcinoma.

Adenocarcinoma↗
PubMed1977

Laryngeal incompetence during experimental "relative analgesia" using 50% nitrous oxide in oxygen. A preliminary report.

Ten healthy adult volunteers inhaled 50% nitrous oxide in oxygen while dental treatment was simulated for a period of 30 min. During this time 15 ml of radio-opaque dye was placed at the back of the tongue. A similar control study was performed 1 week later, the subjects inhaling pure oxygen without nitrous oxide. X-ray examination revealed that two of the 10 volunteers had aspirated dye while breathing nitrous oxide and oxygen, but no aspiration was apparent in the control study.

Adolescent↗
PubMed1977

Chronic peritoneal dialysis in the management of diabetics with terminal renal failure.

Twelve diabetics with terminal renal failure were maintained on chronic peritoneal dialysis (PD) for 2-28 months (average 10 months). 7/12 survived more than 1 year. Blood glucose levels were well controlled by the use of supplemental, intradialysis, intraperitoneal insulin. The incidence of dialysis-related complications, including peritonitis was not significantly higher than in controls. Neurophysiological studies revealed a high incidence of neuropathy initially with progression in most patients. Radiological studies revealed initial vascular calcifications in 7 out of 12 patients with progression in 4. Retinopathy did not progress significantly. PD is a suitable alternative to hemodialysis in the management of end-stage diabetic nephropathy.

Adult↗
PubMed1977

Fact and fiction.

Explore the source record for details and available documents.

Authorship↗